...main challenge with ICBs is to improve efficacy, seeing that the majority of patients are resistant to therapy. Analysis of solid tumors & the tumor microenvironment have shown that responses are limited to patients with “hot” tumors, with prominent
Immunotherapy as we know now.... is it just the beginning?
Interesting comment from @NatureComms, depicting opportunities & challenges for cancer immunotherapy in the next 10 years A lot of work needed to extend responses to “cold” tumors, but rewards promise to be worth the effort @OncoAlert https://t.
In the past decade, oncology "has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality." Via @NatureComms https://t.co/5LLeKJoRVe https://t.co/0v5DcGUPFF
What companies are on the track?
"As cancer immunotherapeutic research continues, we expect an increasing reliance on synthetic biology." https://t.co/UdmpNd3RBq
Cancer immunotherapy comes of age and looks for maturity | Nature Communications https://t.co/lHzYD6kbqG
¡Publicado hoy! @NatureNews @NatureRevCancer Hemos sido testigos de la transición de la #inmunoterapia contra el #Cáncer; de ser un #SueñoImposible a una potente modalidad establecida de #TratamientovsCáncer. https://t.co/wPlf8OrunJ https://t.co/qjlbcHy